Lithium attenuates IFN-β production and antiviral response via inhibition of TANK-binding kinase 1 kinase activity

Journal of Immunology

Volumn 191, Issue 8, 2013, Pages 4392-4398

  Wang, Lijuan ^a   Zhang, Lei ^a   Zhao, Xueying ^a   Zhang, Meng ^a   Zhao, Wei ^a   Gao, Chengjiang ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BINDING PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; INTERFERON REGULATORY FACTOR 3; LITHIUM; TANK BINDING KINASE 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SENDAI VIRUS; SENDAI VIRUS INFECTION; VESICULAR STOMATITIS; VIRUS IDENTIFICATION; VIRUS REPLICATION;

ANIMALS; CELL LINE; ENZYME ACTIVATION; GLYCOGEN SYNTHASE KINASE 3; HEK293 CELLS; HUMANS; IMMUNITY, INNATE; INTERFERON REGULATORY FACTOR-3; INTERFERON-BETA; LIPOPOLYSACCHARIDES; LITHIUM CHLORIDE; MACROPHAGES; MICE; MICE, INBRED C57BL; MONOCYTES; POLY I-C; PROTEIN-SERINE-THREONINE KINASES; RESPIROVIRUS INFECTIONS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SENDAI VIRUS; SIGNAL TRANSDUCTION; VESICULAR STOMATITIS INDIANA VIRUS; VIRUS REPLICATION;

EID: 84885454245     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203142     Document Type: Article

References (48)

1. Akira, S., S. Uematsu, and O. Takeuchi. 2006. Pathogen recognition and innate immunity. Cell 124: 783-801.
2. O'Neill, L. A. 2008. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol. Rev. 226: 10-18.
3. Kawai, T., and S. Akira. 2010. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11: 373-384.
4. Loo, Y. M., and M. Gale, Jr. 2011. Immune signaling by RIG-I-like receptors. Immunity 34: 680-692.
5. Jope, R. S. 1999. Anti-bipolar therapy: mechanism of action of lithium. Mol. Psychiatry 4: 117-128.
6. Klein, P. S., and D. A. Melton. 1996. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA 93: 8455-8459.
7. Forde, J. E., and T. C. Dale. 2007. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell. Mol. Life Sci. 64: 1930-1944.
8. Rayasam, G. V., V. K. Tulasi, R. Sodhi, J. A. Davis, and A. Ray. 2009. Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol. 156: 885-898.
9. Beurel, E., S. M. Michalek, and R. S. Jope. 2010. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol. 31: 24-31.
10. Martin, M., K. Rehani, R. S. Jope, and S. M. Michalek. 2005. Toll-like receptormediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6: 777-784.
11. Wang, H., C. A. Garcia, K. Rehani, C. Cekic, P. Alard, D. F. Kinane, T. Mitchell, and M. Martin. 2008. IFN-b production by TLR4-stimulated innate immune cells is negatively regulated by GSK3-b. J. Immunol. 181: 6797-6802.
12. Lei, C. Q., B. Zhong, Y. Zhang, J. Zhang, S. Wang, and H. B. Shu. 2010. Glycogen synthase kinase 3b regulates IRF3 transcription factor-mediated antiviral response via activation of the kinase TBK1. Immunity 33: 878-889.
13. Yanagita, T., T. Maruta, Y. Uezono, S. Satoh, N. Yoshikawa, T. Nemoto, H. Kobayashi, and A.Wada. 2007. Lithium inhibits function of voltage-dependent sodium channels and catecholamine secretion independent of glycogen synthase kinase-3 in adrenal chromaffin cells. Neuropharmacology 53: 881-889.
14. Li, J., Z. Khavandgar, S. H. Lin, and M. Murshed. 2011. Lithium chloride attenuates BMP-2 signaling and inhibits osteogenic differentiation through a novel WNT/GSK3-independent mechanism. Bone 48: 321-331.
15. Kajda, P. K., N. J. Birch, M. J. O'Brien, and R. P. Hullin. 1979. Rat-brain pyruvate kinase: purification and effects of lithium. J. Inorg. Biochem. 11: 361-366.
16. Phiel, C. J., and P. S. Klein. 2001. Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol. 41: 789-813.
17. Sarkar, S., R. A. Floto, Z. Berger, S. Imarisio, A. Cordenier, M. Pasco, L. J. Cook, and D. C. Rubinsztein. 2005. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 170: 1101-1111.
18. Zhao, W., L. Wang, M. Zhang, P. Wang, C. Yuan, J. Qi, H. Meng, and C. Gao. 2012. Tripartite motif-containing protein 38 negatively regulates TLR3/4-And RIG-I-mediated IFN-b production and antiviral response by targeting NAP1. J. Immunol. 188: 5311-5318.
19. Zhao, W., L. Wang, L. Zhang, C. Yuan, P. C. Kuo, and C. Gao. 2010. Differential expression of intracellular and secreted osteopontin isoforms by murine macrophages in response to Toll-like receptor agonists. J. Biol. Chem. 285: 20452-20461.
20. Zhang, M., L. Wang, X. Zhao, K. Zhao, H. Meng, W. Zhao, and C. Gao. 2012. TRAF-interacting protein (TRIP) negatively regulates IFN-b production and antiviral response by promoting proteasomal degradation of TANK-binding kinase 1. J. Exp. Med. 209: 1703-1711.
21. Chen, H., H. Sun, F. You, W. Sun, X. Zhou, L. Chen, J. Yang, Y. Wang, H. Tang, Y. Guan, et al. 2011. Activation of STAT6 by STING is critical for antiviral innate immunity. Cell 147: 436-446.
22. Doyle, S., S. Vaidya, R. O'Connell, H. Dadgostar, P. Dempsey, T. Wu, G. Rao, R. Sun, M. Haberland, R. Modlin, and G. Cheng. 2002. IRF3 mediates a TLR3/ TLR4-specific antiviral gene program. Immunity 17: 251-263.
23. Platanias, L. C. 2005. Mechanisms of type-I-And type-II-interferon- mediated signalling. Nat. Rev. Immunol. 5: 375-386.
24. Fitzgerald, K. A., S. M. McWhirter, K. L. Faia, D. C. Rowe, E. Latz, D. T. Golenbock, A. J. Coyle, S. M. Liao, and T. Maniatis. 2003. IKKε and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4: 491-496.
25. Stetson, D. B., and R. Medzhitov. 2006. Type I interferons in host defense. Immunity 25: 373-381.
26. Zhao, W. 2013. Negative regulation of TBK1-mediated antiviral immunity. FEBS Lett. 587: 542-548.
27. Gabhann, J. N., R. Higgs, K. Brennan, W. Thomas, J. E. Damen, N. Ben Larbi, G. Krystal, and C. A. Jefferies. 2010. Absence of SHIP-1 results in constitutive phosphorylation of tank-binding kinase 1 and enhanced TLR3-dependent IFN-b production. J. Immunol. 184: 2314-2320.
28. Zhao, Y., L. Liang, Y. Fan, S. Sun, L. An, Z. Shi, J. Cheng, W. Jia, W. Sun, Y. Mori-Akiyama, et al. 2012. PPM1B negatively regulates antiviral response via dephosphorylating TBK1. Cell. Signal. 24: 2197-2204.
29. Li, S., L. Wang, M. Berman, Y. Y. Kong, and M. E. Dorf. 2011. Mapping a dynamic innate immunity protein interaction network regulating type I interferon production. Immunity 35: 426-440.
30. Wang, C., T. Chen, J. Zhang, M. Yang, N. Li, X. Xu, and X. Cao. 2009. The E3 ubiquitin ligase Nrdp1 "preferentially" promotes TLR-mediated production of type I interferon. Nat. Immunol. 10: 744-752.
31. Saitoh, T., M. Yamamoto, M. Miyagishi, K. Taira, M. Nakanishi, T. Fujita, S. Akira, N. Yamamoto, and S. Yamaoka. 2005. A20 is a negative regulator of IFN regulatory factor 3 signaling. J. Immunol. 174: 1507-1512.
32. Parvatiyar, K., G. N. Barber, and E. W. Harhaj. 2010. TAX1BP1 and A20 inhibit antiviral signaling by targeting TBK1-IKKi kinases. J. Biol. Chem. 285: 14999-15009.
33. Gao, L., H. Coope, S. Grant, A. Ma, S. C. Ley, and E. W. Harhaj. 2011. ABIN1 protein cooperates with TAX1BP1 and A20 proteins to inhibit antiviral signaling. J. Biol. Chem. 286: 36592-36602.
34. Cui, J., Y. Li, L. Zhu, D. Liu, Z. Songyang, H. Y. Wang, and R. F. Wang. 2012. NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4. Nat. Immunol. 13: 387-395.
35. McCoy, C. E., S. Carpenter, E. M. Pålsson-McDermott, L. J. Gearing, and L. A. O'Neill. 2008. Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and-4 by targeting TBK1 activation. J. Biol. Chem. 283: 14277-14285.
36. Youn, H. S., J. Y. Lee, K. A. Fitzgerald, H. A. Young, S. Akira, and D. H. Hwang. 2005. Specific inhibition of MyD88-independent signaling pathways of TLR3 and TLR4 by resveratrol: molecular targets are TBK1 and RIP1 in TRIF complex. J. Immunol. 175: 3339-3346.
37. Ng, S. L., B. A. Friedman, S. Schmid, J. Gertz, R. M. Myers, B. R. Tenoever, and T. Maniatis. 2011. IkB kinase ε (IKKε) regulates the balance between type I and type II interferon responses. Proc. Natl. Acad. Sci. USA 108: 21170-21175.
38. Tenoever, B. R., S. L. Ng,M. A. Chua, S. M. McWhirter, A. García-Sastre, and T. Maniatis. 2007. Multiple functions of the IKK-related kinase IKKε in interferon-mediated antiviral immunity. Science 315: 1274-1278.
39. Larabi, A., J. M. Devos, S. L. Ng, M. H. Nanao, A. Round, T. Maniatis, and D. Panne. 2013. Crystal structure and mechanism of activation of TANK-binding kinase 1. Cell Rep 3: 734-746.
40. Ryves, W. J., and A. J. Harwood. 2001. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Commun. 280: 720-725.
41. Lan, Y., X. Liu, R. Zhang, K. Wang, Y. Wang, and Z. C. Hua. 2013. Lithium enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells. Biometals 26: 241-254.
42. Dudev, T., and C. Lim. 2011. Competition between Li+ and Mg2+ in metalloproteins. Implications for lithium therapy. J. Am. Chem. Soc. 133: 9506-9515.
43. Meffre, D., J. Grenier, S. Bernard, F. Courtin, T. Dudev, G. Shackleford, M. Jafarian-Tehrani, and C. Massaad. 2013. Wnt and lithium: a common destiny in the therapy of nervous system pathologies? Cell. Mol. Life Sci. DOI: 10.1007/ s00018-013-1378-1.
44. Clément-Lacroix, P., M. Ai, F. Morvan, S. Roman-Roman, B. Vayssière, C. Belleville, K. Estrera, M. L. Warman, R. Baron, and G. Rawadi. 2005. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc. Natl. Acad. Sci. USA 102: 17406-17411.
45. Edwards, C. M., J. R. Edwards, S. T. Lwin, J. Esparza, B. O. Oyajobi, B. McCluskey, S. Munoz, B. Grubbs, and G. R. Mundy. 2008. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 111: 2833-2842.
46. De Sarno, P., X. Li, and R. S. Jope. 2002. Regulation of Akt and glycogen synthase kinase-3b phosphorylation by sodium valproate and lithium. Neuropharmacology 43: 1158-1164.
47. De Sarno, P., R. C. Axtell, C. Raman, K. A. Roth, D. R. Alessi, and R. S. Jope. 2008. Lithium prevents and ameliorates experimental autoimmune encephalomyelitis. J. Immunol. 181: 338-345.
48. González-Navajas, J. M., J. Lee, M. David, and E. Raz. 2012. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 12: 125-135.